Laurus Labs is ramping up its Research and Development (R&D) capabilities, focusing on a significant array of new products.
According to Satyanarayana Chava, Founder and CEO, Laurus Labs, the company is committed to investing in its portfolio through a product-specific strategy that considers complexity and economies of scale.
Chava stated, “We have a total of sixty-two products in our R&D pipeline, either under review or in development, targeting a substantial addressable market size”.
New R&D Center in Hyderabad
In October, Laurus Labs opened a new small molecule R&D center at ICICI Knowledge Park in Hyderabad, which provides comprehensive development and manufacturing service, using state-of-the-art technology.
The new center attracted significant interest from existing biopharma customers for early-stage process development work.
Advanced Capabilities to Support Growth
The Hyderabad-based drug maker will utilize advanced techniques such as flow chemistry, biocatalysis, and high-potency chemistry at this new facility.
These capabilities will help Laurus secure early-stage projects, broaden its project funnel, and meet the increasing demands of global partners.
Additionally, Laurus has expanded its fermentation site by adding a new pilot plant, which will optimize capacity.
“Our plans to increase fermentation capacity are on track to capitalize on GMP manufacturing opportunities,” Chava confirmed.
Commitment to Quality and Regulatory Standards
Laurus underwent nearly 76 quality audits by various regulatory agencies and customers, and passing inspections without any critical findings.
Laurus is progressing towards becoming a diversified Contract Development and Manufacturing Organization (CDMO), meeting the complex needs of its customers.
As reported by thehindubusinessline.com, the brand is reinforcing growth by executing long-term investment strategy, enhancing development expertise and building integrated large-scale manufacturing capabilities.
